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ABSTRACT
Blood pressure (BP) is elevated in 75% or more of
patients with acute stroke and is associated with poor
outcomes. Whether to modulate BP in acute stroke has
long been debated. With the loss of normal cerebral
autoregulation, theoretical concerns are twofold: high
BP can lead to cerebral oedema, haematoma expansion
or haemorrhagic transformation; and low BP can lead
to increased cerebral infarction or perihaematomal
ischaemia. Published evidence from multiple large,
high-quality, randomised trials is increasing our
understanding of this challenging area, such that BP
lowering is recommended in acute intracerebral
haemorrhage and is safe in ischaemic stroke. Here we
review the evidence for BP modulation in acute stroke,
discuss the issues raised and look to on-going and
future research to identify patient subgroups who are
most likely to benefit.
BACKGROUND
Stroke has a global incidence of 15 million
people per year, is the third leading cause of
death and is the most common cause of dis-
ability in the western world.1 High-blood
pressure (BP) is the leading modiﬁable risk
factor for both ischaemic and haemorrhagic
stroke2 affecting 1 billion people worldwide.3
In acute stroke, 75% of patients have high
BP and 50% of those have a prior history of
hypertension.4 5 Although BP spontaneously
falls in two-thirds of patients in the ﬁrst week
following stroke,4 one-third remain hyperten-
sive and have an increased risk of a poor
outcome.6 Data from the ﬁrst International
Stroke Trial demonstrated a U-shaped rela-
tionship between baseline systolic BP (SBP)
and outcome, such that both high and low
SBP were independently associated with
increased early death and late death or
dependency.7 In addition, high SBP is asso-
ciated with an increased risk of early stroke
recurrence.7 8 Post hoc analyses from several
acute stroke clinical trials suggest that as well
as increased SBP, other haemodynamic vari-
ables including higher peak SBP, mean arter-
ial pressure (MAP), pulse pressure and
increased SBP variability, are each associated
with poor functional outcome,9 early
neurological deterioration,10 recurrent stroke
and death.11
The acute hypertensive response seen in
stroke has numerous potential causes includ-
ing: ﬂuctuations in, or elevation of, pre-
existing hypertension; infection; pain, for
example, due to urinary retention; stress
related to hospitalisation; activation of corti-
sol, natriuretic peptide, renin–angiotensin–
aldosterone and sympathetic neuroendocrine
systems; impaired cardiac baroreceptor sensi-
tivity; and raised intracranial pressure
(Cushing’s reﬂex).12–15 Although low BP is
far less common in acute stroke, it is asso-
ciated with a poor outcome.7 Potential
causes include sepsis, cardiac arrhythmias,
heart failure and ischaemia, hypovolaemia
and aortic dissection.16
Normal cerebral autoregulation, which
maintains cerebral blood ﬂow (CBF) despite
ﬂuctuations in cerebral perfusion pressure
(CPP) between 50 and 150 mm Hg, is
impaired in acute stroke resulting in cerebral
perfusion having a linear relationship with
CPP and therefore MAP.17 Rapid, large falls
in BP could reduce CBF leading to extension
of cerebral infarction,18 or perihaematomal
ischaemia.19 Equally, with higher BP there is
increased risk of haematoma expansion in
intracerebral haemorrhage (ICH), haemor-
rhagic transformation in animal models of
ischaemic stroke (IS) and cerebral oedema,
in both types of stroke.6 20
The debate surrounding whether high BP
should or should not be treated in the context
of acute stroke started over 30 years ago21 22
and despite large clinical trials the answer
remains largely unclear. In this review, we
discuss the evidence for BP modulation in
acute stroke, the challenges and issues raised,
and look to on-going and future trials that may
provide some clarity in this controversial area.
CLASS ACTION
A variety of BP modulating agents have been
assessed in the context of acute stroke
(table 1).23
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α-2-adrenoreceptor agonists
The α-2-adrenoreceptor agonist, clonidine, was tested in
a small randomised controlled trial (RCT), which allo-
cated 16 participants with middle cerebral artery infarc-
tion within 72 hours of onset and high baseline BP (SBP
170–220 mm Hg, diastolic BP (DBP) 95–120 mm Hg) to
nicardipine 20 mg, captopril 12.5 mg, clonidine 0.1 mg,
or placebo given every 8 hours for 3 days.24 BP fell in all
groups but there was no signiﬁcant difference in BP
between the two main groups and no difference in
stroke outcome, measured using the National Institutes
of Health Stroke Scale (NIHSS), over the 3 days of treat-
ment. To date, no large RCTs have assessed the use of
α-2-adrenoreceptor agonists in acute stroke.
ACE inhibitors
In three small RCTs of acute IS (AIS) oral perindopril,43
lisinopril44 and captopril24 independently reduced BP,
while preserving CBF, although no differences in neuro-
logical impairment (NIHSS) or functional outcome
(modiﬁed Rankin Scale (mRS)) were seen between
groups.44
The Controlling Hypertension and Hypotension
Immediately Post-Stroke (CHHIPS) trial25 randomised
179 patients with either IS or ICH within 36 hours of
ictus and SBP >160 mm Hg to oral labetalol (50 mg), lisi-
nopril (5 mg) or placebo in those without dysphagia, or
intravenous labetalol (50 mg), sublingual lisinopril
(5 mg), or placebo in those with dysphagia. Dose escal-
ation occurred if participants did not reach target SBP
(145–155 or 15 mm Hg reduction) at 4 and 8 hours
postrandomisation. Lisinopril reduced mean BP by 14/
7 mm Hg compared with placebo between randomisa-
tion and 24 hours. Following 14 days of treatment there
was no difference in functional outcome (mRS >3)
between treatment and control (relative risk (RR) 1.03,
95% CI 0.8 to 1.33, p=0.82), although lisinopril was safe
with no increased reporting of serious adverse events.
In the prehospital environment the Paramedic
Initiated Lisinopril For Acute Stroke Treatment
(PIL-FAST) study randomised 14 patients with new uni-
lateral arm weakness within 3 hours of onset and SBP
>160 mm Hg to either sublingual lisinopril (5 mg) or
placebo for a total of 7 days.26 BP fell in the lisinopril
group compared to control by hospital admission and
persisted for the duration of treatment. As a feasibility
trial it was successful but was not powered to assess
efﬁcacy.
Angiotensin receptor antagonists
The Acute Candesartan Cilexetil Therapy in Stroke
Survivors (ACCESS) study,27 randomised 339 partici-
pants with IS and elevated BP (≥180/105 mm Hg) to
7 days of oral candesartan or placebo within 36 hours of
admission. Mortality at 12 months and cardiovascular
events (secondary outcome) were signiﬁcantly reduced
in the candesartan arm, although there was no signiﬁ-
cant effect on functional outcome (Barthel index (BI),
primary outcome) at 3 months, or on BP throughout
the 12 months of the trial.
A post hoc subgroup analysis of the multinational
Prevention Regimen for Effectively Avoiding Second
Strokes (PRoFESS) trial28 examined the effect of adding
telmisartan versus placebo to standard antihypertensive
management in 1360 patients with mild IS recruited
within 72 hours of ictus. Telmisartan lowered SBP and
DBP by 6–7 and 2–4 mm Hg respectively compared with
placebo and was safe with no excess of adverse events.
However, telmisartan did not inﬂuence functional
outcome (mRS at day 30, primary outcome) or death,
stroke recurrence and cardiovascular events at days 7, 30
or 90. In contrast to the ACCESS study, PRoFESS partici-
pants had lower BP at randomisation, milder strokes,
enhanced antihypertensive therapy, were recruited later
(58 vs 29 hours) and had a longer period of treatment
(30 months vs 7 days), which may account for the dis-
similar ﬁndings between the trials.
Following ACCESS, the Scandinavian Candesartan
Acute Stroke Trial (SCAST)29 recruited 2029 partici-
pants with acute stroke (IS and ICH) within 30 hours of
onset and SBP ≥140 mm Hg. Patients were randomised
to either candesartan 4 mg with dose escalation up to
16 mg, or placebo for 7 days. BP fell in both groups over
the treatment period and was signiﬁcantly lower in the
candesartan arm compared to placebo (day 7 mean BP:
147/82 vs 152/84 mm Hg). Co-primary end points were
measured at 6 months: a composite of vascular death,
myocardial infarction and stroke was neutral; and func-
tional outcome measured by a shift in mRS suggested a
higher risk of poor outcome in those randomised to
candesartan, but was not statistically signiﬁcant given the
two primary outcomes (adjusted common OR (acOR)
1.17, 95% CI 1.00 to 1.38, p=0.048). A prespeciﬁed sub-
group analysis of those with ICH (n=274) also found
that candesartan was associated with an increased risk of
poor outcome (acOR 1.61, 95% CI 1.03 to 2.50,
p=0.036).45
Several smaller, underpowered trials have assessed can-
desartan,46 irbesartan,47 telmisartan,30 and valsartan48 in
AIS. Telmisartan did not alter CBF or BP acutely.30 The
Valsartan Efﬁcacy oN modesT blood pressUre Reduction
in acute ischaemic stroke (VENTURE) trial,48 rando-
mised 393 South Korean patients with AIS within
24 hours of onset and SBP 150–185 mm Hg to oral val-
sartan 80 mg daily with dose escalation, or placebo for
7 days. Valsartan signiﬁcantly reduced mean DBP at day
7 compared with placebo (83.1 vs 84.8 mm Hg), while
SBP was not signiﬁcantly reduced. The primary outcome
of death or dependency at 90 days (mRS >3) was
neutral, but early neurological deterioration within
7 days was signiﬁcantly higher in the valsartan group
(16.6% vs 6%, OR 2.43, 95% CI 1.25 to 4.73, p=0.008);
mainly due to stroke progression in those with large
artery atherosclerosis as the cause of their stroke and
angiographically conﬁrmed large-artery stenosis or
occlusion.
Appleton JP, et al. Stroke and Vascular Neurology 2016;1:e000020. doi:10.1136/svn-2016-000020 73
Open Access
Table 1 BP modulation by class action
Trial
Stroke type
(IS/ICH) Drug
Time given
(hours) BP effect CBF effect
Clinical
outcome
α2 adrenoreceptor agonist Increase
(rats)
Neutral
Lisk et al (1993)24 IS Clonidine <72 Mean reduction: SBP 13.6, DBP
2.1 mm Hg
ACEi Maintain/
increase
Neutral
CHIPPS 200925 All Lisinopril (PO/SL) <36 (mean 19) Mean reduction: SBP 14 mm Hg
DBP 7 mm Hg
PIL-FAST 201326 All Lisinopril (SL/PO) <3
ARA Neutral/
reduce
Neutral/poor
ACCESS 200327 IS Candesartan (PO) <36 (mean 29) No difference
PRoFESS 200928 IS Telmisartan (PO) <72 (mean 58) SBP: 6–7 mm Hg
DBP: 2–4 mm Hg
SCAST 201129 All Candesartan (PO) <30 (mean 18) Mean difference at 7 days: SBP
5 mm Hg
DBP 2 mm Hg
VENTURE 201530 IS Valsartan (PO) <24 (mean 12) Mean difference at 7 days: SBP
4 mm Hg
DBP 2 mm Hg
α and β-Blocker Neutral Neutral
CHIPPS 200925 All Labetalol (PO/IV) <36 (mean 19) Mean reduction: SBP 7 mm Hg
DBP increase 0.6 mm Hg
β-Blockers ?Reduce Poor
BEST 198831 Unknown Propranolol (PO),
atenolol (PO)
<48 Reduction: 6–9% vs 2% (placebo)
CCA Reduce Poor
INWEST 199432 IS Nimodipine (IV) 1 mg/
hour (low dose), 2 mg/
hour (high dose)
<24 SBP low dose: 6.6%; high dose
11.4%; placebo 2.1%
DBP low dose 7.7%; high 14.1%;
placebo 1.7%;
VENUS 200133 All Nimodipine (PO) <6 No difference
Systematic review (Horn 2001)34 IS Poor
Diuretics Neutral Neutral
Eames et al (2005)35 IS Bendroflumethiazide
(PO)
<96 No difference
Magnesium Increase Neutral
IMAGES 200436 IS Magnesium sulfate IV
bolus and infusion
<12 (median 7) BP difference at 24: 4/3 mm Hg vs
placebo
FAST-MAG 201537 All Magnesium sulfate IV
bolus and infusion
<2 (median
45 min)
SBP difference at 24: 3 mm Hg
Continued
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These neutral and negative ﬁndings may indicate that
angiotensin receptor antagonists (ARAs) have undesir-
able properties in acute stroke or that gradual and late
treatment of BP is ‘too little too late’, thus reducing
cerebral perfusion and increasing brain injury.
β-blockers
The single-centre β-blocker stroke (BEST) trial31 rando-
mised 302 patients with clinically diagnosed strokes
within 48 hours of onset to oral propranolol, atenolol or
placebo. There was a greater fall in mean BP in the ﬁrst
24 hours of treatment (6–9% vs 2%) and an increase in
early and later death in those assigned to β-blockers
compared to placebo. The negative inotropic effects of
β-blockers may worsen cerebral perfusion in acute stroke
and thus explain this ﬁnding, although pathophysio-
logical trial data are lacking (table 2).
In those randomised to labetalol (a mixed α and β
adrenergic antagonist) in the CHHIPS trial,25 SBP fell
by 7 mm Hg at 24 hours. In contrast to the BEST trial,
labetalol was safe with no increase in serious adverse
events, early neurological deterioration or death.
Overall, the active treatment group (labetalol and lisino-
pril combined) had reduced 90-day mortality compared
to the placebo group (HR 0.40, 95% CI 0.2 to 1.0,
p=0.05) but the study was not powered for this outcome.
Calcium channel antagonists
Early studies showed signiﬁcant drops in BP in patients
who received nimodipine66 or nicardipine,24 with the
latter suggesting that large drops in BP due to nicardi-
pine were associated with reduced regional CBF to
infarcted tissue. Contrary to this, other small trials
reported positive results of oral67 68 and intravenous
nimodipine69 on long-term recovery in AIS, prompting
the need for a larger RCT.
The Intravenous Nimodipine West European Stroke
Trial (INWEST)32 randomised 295 patients with AIS
within 24 hours of onset to intravenous nimodipine at
1 mg/hour (low dose) or 2 mg/hour (high dose) for
5 days then 120 mg daily (orally) for a total of 21 days,
or placebo. Recruitment was stopped early due to statis-
tically signiﬁcant unfavourable functional outcomes (BI
and Orgogozo neurological impairment scale) in the
nimodipine groups compared with placebo at both
21 days and 6 months. Over the ﬁrst 2 days, mean BP sig-
niﬁcantly fell from baseline in the treatment arms com-
pared with placebo.70 In a subsequent analysis, DBP
reduction in the high-dose treatment arm was associated
with a poor functional outcome at day 21, while those
who received high-dose nimodipine and had a large
(≥20%) fall in DBP had an increased risk of death or
dependency and death at day 21.70 A similar but unpub-
lished trial in the USA had comparable results.71
A further trial of oral nimodipine recruited 454
patients within 6 hours of stroke ictus in primary care.33
At 24 hours there was no signiﬁcant difference in BP
between the nimodipine and control groups, and the
Ta
b
le
1
Co
nt
in
ue
d
Tr
ia
l
S
tr
o
ke
ty
p
e
(IS
/IC
H
)
D
ru
g
T
im
e
g
iv
en
(h
o
u
rs
)
B
P
ef
fe
ct
C
B
F
ef
fe
ct
C
lin
ic
al
o
u
tc
o
m
e
N
O
do
no
rs
In
cr
ea
se
N
eu
tr
al
?e
ar
ly
ef
fe
ct
R
IG
H
T
20
13
3
8
A
ll
G
T
N
5
m
g
to
pi
ca
lp
at
ch
<
6
(m
ed
ia
n
55
m
in
)
S
B
P
di
ffe
re
nc
e
at
2:
18
m
m
H
g
E
N
O
S
20
14
3
9
A
ll
G
T
N
5
m
g
to
pi
ca
lp
at
ch
<
48
(m
ed
ia
n
26
)
M
ea
n
re
du
ct
io
n
at
24
:S
B
P
7
m
m
H
g;
D
B
P
3
m
m
H
g
P
re
ss
or
s
H
ill
is
et
al
(2
00
3)
4
0
IS
IV
P
he
ny
le
ph
rin
e
<
1
w
ee
k
N
o
da
ta
In
cr
ea
se
U
nk
no
w
n
S
pr
ig
g
et
al
(2
00
7)
4
1
IS
P
O
A
m
ph
et
am
in
e
3–
30
da
ys
S
B
P
at
90
m
in
in
cr
ea
se
d
by
11
m
m
H
g
N
eu
tr
al
N
eu
tr
al
/p
oo
r
(8
3)
S
ax
en
a
et
al
(1
99
9)
4
2
IS
IV
D
C
LH
b
<
72
M
A
P
at
2
in
cr
ea
se
d
by
21
m
m
H
g
P
oo
r
A
C
E
i,
A
C
E
in
hi
bi
to
rs
in
hi
bi
to
rs
;A
R
A
,a
ng
io
te
ns
in
re
ce
pt
or
an
ta
go
ni
st
s;
B
P
,b
lo
od
pr
es
su
re
;
C
B
F,
ce
re
br
al
bl
oo
d
flo
w
;
C
C
A
,c
al
ci
um
ch
an
ne
la
nt
ag
on
is
ts
;
D
B
P
,d
ia
st
ol
ic
bl
oo
d
pr
es
su
re
;
D
C
LH
b,
di
as
pi
rin
cr
os
s-
lin
ke
d
ha
em
og
lo
bi
n;
G
T
N
,
gl
yc
er
yl
tr
in
itr
at
e;
IC
H
,i
nt
ra
ce
re
br
al
ha
em
or
rh
ag
e;
IS
,
is
ch
ae
m
ic
st
ro
ke
;
iv
,i
nt
ra
ve
no
us
;
po
,o
ra
lly
;N
O
,n
itr
ic
ox
id
e;
S
B
P
,s
ys
to
lic
bl
oo
d
pr
es
su
re
.
Appleton JP, et al. Stroke and Vascular Neurology 2016;1:e000020. doi:10.1136/svn-2016-000020 75
Open Access
primary outcome of death or dependency (mRS >3) at
3 months was neutral (RR 1.2, 95% CI 0.9 to 1.6). This
trial was stopped early because a Cochrane systematic
review involving 7665 patients from 29 trials of calcium
channel antagonists (CCA) in AIS revealed no treatment
effect on functional outcome or death at the end of
follow-up.72 Interestingly, a subgroup analysis of unpub-
lished and methodologically sound trials yielded a statis-
tically signiﬁcant unfavourable treatment effect
indicative of publication bias (RR 1.14, CI 95% 1.0 to
1.3); overall, good quality trials produced a statistically
signiﬁcant negative treatment effect (RR 1.09, 95% CI
1.02 to 1.16).34 Unfortunately, much of the drive to test
CCA, especially nimodipine, was driven by early positive
data.67–69 73
Diuretics
There is limited data on diuretics in acute stroke.23 One
small RCT randomised 37 hypertensive patients with AIS
within 96 hours of onset to bendroﬂumethiazide (a
thiazide-like diuretic) 2.5 mg daily or placebo for
7 days.35 Although mean SBP was lower in the treatment
group compared with placebo within 70 hours of ran-
domisation (156 vs 176 mm Hg), there was no difference
in BP between the arms at day 7. Measures of CBF and
cardiac baroreceptor sensitivity showed no signiﬁcant
change between groups at either time point in the trial,
suggesting that bendroﬂumethiazide is an ineffective
agent for use in acute patients with stroke.
Magnesium
A systematic review of several small pilot studies assessing
magnesium in acute stroke reported a non-signiﬁcant
reduction in death or disability in patients treated with
magnesium (OR 0.73, 95% CI 0.38 to 1.41).74 A large
RCT allocated 2589 patients with AIS within 12 hours of
onset to intravenous magnesium sulfate slow bolus
(16 mmol) followed by infusion (65 mmol) over
24 hours, or placebo.36 Although BP fell by 4/3 mm Hg
between baseline and 24 hours in the magnesium group
compared with placebo, the only signiﬁcant difference
in BP was during the initial infusion. The primary
outcome of death and disability at day 90 (BI <95 and
mRS >1 combined) was neutral, but there was a trend
towards increased mortality in the magnesium group
(HR 1.18, 95% CI 0.97 to 1.42, p=0.098). In a prespeci-
ﬁed subgroup of non-cortical strokes, magnesium signiﬁ-
cantly reduced death and disability (OR 0.75, 95% 0.58
to 0.97, p=0.011); a ﬁnding supported by a post-hoc ana-
lysis where those with lacunar stroke had reduced death
and disability at day 90 (OR 0.7, 95% 0.53 to 0.92,
p=0.0046). Patients who received magnesium within
3 hours of onset had a trend towards a better outcome
(OR 0.66, 95% 0.25 to 1.7, p=0.46).
The Field Administration of Stroke Therapy-Magnesium
(FAST-MAG) trial37 sought to assess magnesium in this
shorter time window by recruiting 1700 patients with pre-
sumed stroke within 2 hours of ictus to intravenous
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magnesium bolus followed by infusion, or placebo. SBP
fell in both groups over the ﬁrst 48 hours but those on
treatment had a signiﬁcantly lower SBP (∼3 mmHg differ-
ence) at the end of the bolus dose and from 20 to
32 hours after starting the maintenance infusion.
Although prehospital initiation of magnesium was safe,
there was no signiﬁcant shift in mRS at day 90 (primary
outcome).
Nitric oxide donors
In three small RCTs in acute stroke, transdermal glyceryl
trinitrate (GTN) lowered BP, pulse pressure and peak
SBP while maintaining CBF and improving arterial com-
pliance.65 76 77 A small ambulance-based feasibility trial
of transdermal GTN administered within 4 hours of
symptom onset revealed an improvement in functional
outcome at 90 days, measured as a shift in mRS by 1
point (p=0.04).38 None of these trials were powered for
functional outcome; this was assessed in the large
Efﬁcacy of Nitric Oxide in Stroke (ENOS) trial.39
ENOS randomised 4011 patients with AIS or ICH within
48 hours of onset and high SBP (140–220 mmHg) to
transdermal GTN 5 mg patches or placebo for 7 days. In
addition, those participants on antihypertensive agents
immediately prior to their stroke were randomised to stop
or continue their medication, in a partial-factorial
design.39 GTN signiﬁcantly reduced both SBP and DBP
day 1 after randomisation compared to placebo (mean dif-
ference: 7 and 3 mmHg, respectively, p<0.001) but there
was no statistically signiﬁcant difference from day 3
onwards. Overall, GTN was safe in both IS and ICH.
Although the primary outcome of mRS at day 90 was
neutral (acOR 1.0, 95% CI 0.91 to 1.13, p=0.83), a prespe-
ciﬁed subgroup analysis found that in those recruited in
<6 hours from ictus, GTN was associated with a favourable
shift in mRS (acOR 0.51, 95% 0.32 to 0.8, p=0.004), less
death and improved cognition, disability, mood and
quality of life.77 Beneﬁcial effects were seen in patients
with IS (including those receiving thrombolysis) and
ICH.78
Pressor therapy
Several small studies have assessed the role of pressor
therapy in AIS.23 79 One trial assessed intravenous
phenylephrine versus conventional management in 15
patients with AIS within 1 week of ictus, >20% diffusion-
perfusion mismatch on MRI and normotension (SBP
<140 mm Hg).40 Phenylephrine was titrated to increase
MAP by 10–20% and maintained for up to 72 hours.
NIHSS and cognitive scores, and volume of hypoper-
fused tissue on MRI, improved in the treatment group
with no signiﬁcant adverse events, but there was no
assessment of functional outcome. The aforementioned
CHHIPS trial had a pressor arm, which sought to assess
phenylephrine in hypotensive patients with IS, but
grossly under-recruited (one participant only, who
received placebo).80 Similarly, an unpublished trial of
dobutamine only managed to recruit three patients.
Diaspirin cross-linked haemoglobin (DCLHb), a cell-
free haemoglobin-based oxygen-carrying solution that
scavenges NO,81 was compared with saline in 85 patients
with AIS within 18 hours of onset.42 DCLHb caused a
rapid rise in BP and more serious adverse events, disabil-
ity (BI), death and poor functional outcome (mRS) at
3 months than control. In a small RCT of 33 patients
within 1 month of IS,41 amphetamine raised BP and
heart rate but had no impact on motor function or
functional outcome. Although amphetamine was asso-
ciated with a trend to improved motor function after IS
in a systematic review, there was a non-signiﬁcant
increase in death, raising doubts over its safety.82 Other
potential agents including norepinephrine (noradren-
aline), epinephrine (adrenaline) and dopamine have no
signiﬁcant evidence base.79
TARGETTING BP IN ACUTE STROKE
An alternative avenue of research has focused on
whether aiming for a BP target in acute stroke, regard-
less of the agent(s) used, improves outcome.
Ischaemic stroke
The China Antihypertensive Trial in Acute Ischaemic
Stroke (CATIS)83 recruited 4071 patients with AIS with
raised SBP (140–220 mm Hg) within 48 hours of onset
and randomised them to either BP lowering (SBP
10–25% reduction within 24 hours and BP <140/
90 mm Hg within 7 days) or control (no antihypertensive
medication). Although a speciﬁc BP-lowering regimen
was not being assessed they suggested ﬁrst-line (intraven-
ous ACEi), second-line (oral CCA) and third-line (oral
diuretic) medications. Mean SBP fell by 13% within
24 hours of randomisation in the treatment group, com-
pared with 7% in the control population. At 7 days,
mean SBP in the treatment and control arms was 137
and 147 mm Hg respectively. The primary outcome of
mRS ≥3 at 14 days or hospital discharge and secondary
outcome of mRS at day 90 were neutral. A subgroup
analysis of time to treatment found that those rando-
mised to BP lowering 24 hours or longer after ictus had
a signiﬁcant reduction in death or dependency at
3 months (OR 0.73, 95% CI 0.55 to 0.97, p=0.03).83
There are several points to mention. First, the recruits
had minor strokes (median NIHSS 4) resulting in 66%
of the control population being independent at 2 weeks
and therefore reducing the potential for the interven-
tion to show beneﬁt. Second, patients with large vessel
carotid disease were omitted from the trial. And last,
patients receiving thrombolysis were excluded, further
limiting the trial’s generalisability.83
Intracerebral haemorrhage
In a small feasibility study of patients with ICH within
8 hours of symptom onset, aggressive BP lowering (MAP
<110 mm Hg) was safe with no difference in rates of
early neurological deterioration, haematoma expansion
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or cerebral oedema.84 The concern surrounding
whether aggressive BP lowering compromises perihae-
matoma CBF was addressed in the Intracerebral
Haemorrhage Acutely Decreasing Arterial Pressure Trial
(ICH-ADAPT).85 Seventy-ﬁve patients with spontaneous
ICH within 24 hours of onset and high BP (SBP
≥150 mm Hg) were randomised to a target SBP of <150
or <180 mm Hg within 1 hour of randomisation. Two
hours after recruitment CT perfusion imaging revealed
reduced CBF and cerebral blood volume within the peri-
haematoma region compared with the contralateral
homologous area in all patients. There was no signiﬁ-
cant difference in relative CBF between the groups, indi-
cating that aggressive BP reduction in ICH did not, at
least in this study, precipitate perihaematomal
ischaemia.85
Early BP lowering in the Intensive Blood Pressure
Reduction in Acute Cerebral Haemorrhage Trial
(INTERACT)86 involving 404 patients was safe, feasible
and seemed to reduce haematoma growth. Similarly,
BP reduction within 6 hours in the Antihypertensive
Treatment of Acute Cerebral Haemorrhage (ATACH)87
study was safe. The magnitude of SBP lowering was
associated with less haematoma expansion and
improved functional outcome.88 The largest trial of
intensive BP lowering in ICH, INTERACT2,89 recruited
2839 patients within 6 hours of onset with high SBP
(150–220 mm Hg) and randomised them to guideline
therapy (SBP <180 mm Hg) or intensive therapy (SBP
<140 mm Hg within 1 hour) for 7 days using oral or
intravenous agents at the discretion of the local investi-
gator. At 1 hour, a third of patients in the intensive
arm achieved the target SBP of <140 mm Hg with a
mean SBP of 150 mm Hg, compared with 164 mm Hg
in the guideline group. The primary outcome of death
or major disability (mRS ≥3 at 90 days) was neutral,
but a prespeciﬁed ordinal shift analysis of mRS
revealed a favourable shift in those randomised to
intensive BP lowering (OR 0.87, 95% CI 0.77 to 1.00,
p=0.04). In addition, better outcomes were seen in
those with larger BP reductions within 1 hour of ran-
domisation.90 Intensive BP reduction was safe with no
difference in death or other serious adverse events
between groups.89
The use of mannitol in 62% of INTERACT2 partici-
pants is unclear given that the overall 24 hours median
haematoma volume was 20 mL, making intracranial
hypertension unlikely. The myriad combinations of anti-
hypertensive agents used in the trial included one rarely
used in the West (Urapidil) and others with potentially
negative or harmful effects, which may have confounded
the BP-lowering effect.91
While INTERACT2 did not show any change in
haematoma expansion with aggressive BP lowering, a
meta-analysis of four of the above trials84–86 89 found
that intensive BP lowering in acute ICH appeared safe
with a tendency towards improved functional
outcome; an effect which may have been mediated
through attenuation of haematoma expansion
observed at 24 hours in both unadjusted and adjusted
models.92 Furthermore, a post hoc analysis of
INTERACT2 revealed that intensive BP lowering with
greater SBP reduction prevented haematoma growth
at 24 hours.93
ISSUES
To treat or not to treat?
Guidelines suggest that BP lowering in acute stroke
should be postponed for days or even weeks unless BP is
grossly elevated (>220/120 mm Hg), or >200/100 with
concomitant evidence of acute kidney injury, aortic dis-
section, cardiac ischaemia, hypertensive encephalopathy
or pulmonary oedema.94–96
Thrombolysis for hyper-acute ischaemic stroke
In the context of thrombolysis in AIS, BP must be <185/
110 mmHg prior to administration of alteplase, and
<180/105 mmHg for the following 24 hours; suggested
methods involve using intravenous labetalol, nicardipine
or nitroprusside.94 Unfortunately there is a paucity of evi-
dence and this recommendation is based on expert
opinion with extrapolation from trials of thrombolysis in
myocardial infarction.97 98 Observational data from the
Safe Implementation of Thrombolysis in Stroke (SITS)
register99 100 revealed that a higher SBP post-thrombolysis
is associated with symptomatic ICH and poor outcome. A
U-shaped relationship was seen between SBP 2–24 hours
after thrombolysis and major disability and death, with the
most favourable outcomes occurring in those with SBP
141–150 mmHg.100 The on-going Enhanced Control of
Hypertension and Thrombolysis in Stroke Study
(ENCHANTED)101 will provide insight into whether acute
intensive lowering of BP (target SBP 130–140 mmHg) has
superior efﬁcacy and lower risk of ICH than guideline
management (SBP <180 mmHg).
Intracerebral haemorrhage
In ICH, both American102 and European103 guidelines
recommend acute lowering of SBP to ≤140 mm Hg
within 6 hours of onset. This guidance is largely driven
by the results of the INTERACT2 trial.89
Race and ethnicity
Demographics are important and especially relevant in a
cosmopolitan global community. For example, Chinese
patients with stroke tend to be younger, smoke more, have
increased intracranial atherosclerosis, less cervical athero-
sclerosis and a higher risk of ICH than their Caucasian
counterparts.104 105 Hence, demographic similarities and
differences should be considered in both future trials and
individual patient data meta-analyses.
Time to treatment
In a recent Cochrane review, lowering BP in 15 432 patients
with acute stroke did not improve outcome regardless of
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stroke type, or drug class and BP target used.23 However, in
those who received treatment within 6 hours of stroke
onset (INTERACT2 and RIGHT), there was a tendency
towards a shift to less death or dependency, and improved
quality of life.38 89 All drug classes described above lowered
BP, with greater reductions seen in ICH than patients with
AIS (−11.8/−5.1 vs −7/−3.1 mm Hg). Smaller BP changes
occurred in patients recruited after 48 hours of onset,
while the largest BP reduction was seen in those recruited
earliest. Importantly, large falls in BP (>20%), especially in
AIS, were associated with a poor outcome.23
A subsequent subgroup analysis of ENOS patients rando-
mised to GTN within 6 hours adds weight to the argument
for early treatment with reduced death or dependency, less
death and improved cognition, disability, mood and quality
of life.77 It is unclear whether this may represent a generic
effect of early BP lowering or a speciﬁc effect of GTN. In
contrast, other interventions namely ARA, β-blockers and
CCA may be detrimental (table 2).29 31 34 45 72
Time is important: ultra-acute treatment of BP (intensive
BP lowering or use of an appropriate agent) within the ﬁrst
few hours of symptoms in the prehospital setting is a vital
avenue to explore further. Non-oral routes of administra-
tion, such as transdermal, sublingual and intravenous,
would be preferable in this context, given the need for a
swallowing assessment to rule out dysphagia. Of these, trans-
dermal GTN,38 sublingual lisinopril,26 and intravenous mag-
nesium,37 have been assessed in the prehospital
environment and found to be safe. While transdermal pre-
parations can be easily applied and removed according to
clinical need, intravenous administration of BP-lowering
agents require intensive monitoring. On-going (RIGHT-2:
ISRCTN26986053) and planned trials of transdermal GTN
in ultra-acute stroke will assess efﬁcacy in the ﬁeld.
BP management in carotid disease and large vessel
occlusion
High BP is commonly seen in patients with AIS due to
carotid artery stenosis.106 Owing to dysfunctional cere-
bral autoregulation concerns are twofold: a higher
systemic BP will result in a higher cerebral perfusion
pressure increasing the risk of cerebral oedema and
potential for haemorrhagic transformation; while lower-
ing BP may reduce CBF resulting in infarct extension.6
A prespeciﬁed subgroup analysis from SCAST of
patients with carotid imaging (n=993 (57%)), revealed
that those with severe unilateral stenosis (≥70%) who
received candesartan had a trend towards increased risk
of stroke progression and poor functional outcome,
although the CI were wide.107 Whether this was due to a
speciﬁc effect of candesartan, or to BP lowering per se
remains unclear. Of the 2038 participants in ENOS with
carotid imaging data, GTN was safe with no evidence of
harm across all levels of ipsilateral carotid stenosis.39
Patients with bilateral severe carotid stenosis pose
another dilemma. A meta-analysis of three trials found
that in patients with bilateral severe stenosis (≥70%), a
lower BP was associated with higher stroke recurrence
(SBP <130 mm Hg: HR 5.97, 95% CI 2.43 to 14.68,
p<0.001).106 Although bilateral carotid stenosis is
uncommon, caution regarding BP lowering in this
group seems warranted pending further data.
With the advent and proven effectiveness of endovas-
cular intervention for proximal anterior circulation
vessel occlusions in AIS,108 numerous questions remain
unanswered, including how BP should be managed
before, during and after thrombectomy. At present this
is an evidence-free zone. Retrospective data comparing
general with local anaesthesia during the procedure
found that general anaesthesia, which was often asso-
ciated with SBP <140 mm Hg, was associated with a poor
functional outcome (mRS >2) at 90 days.109 Prospective
research in this area should prove illuminating.
Continue or stop pre-stroke antihypertensives
Whether to temporarily stop or continue existing antihy-
pertensive agents early after a patient’s stroke is a
common clinical question. The Continue or Stop
Post-Stroke Antihypertensives Collaborative Study
(COSSACS)110 randomised 763 patients within 48 hours
Summary box: BP agents of choice in acute stroke
Acute ischaemic stroke (AIS) Avoid large falls (>20%) in BP.
Aim for gradual BP reduction (5–15%).
Intracerebral haemorrhage (ICH) Rapid lowering of BP to ≤140 mm Hg within 6 hours of onset.
Intravenous agents Require continuous cardiac monitoring.
Labetalol 10–20 mg bolus, over 1–2 min. Further boluses can be given
every 10 min, titrated to BP effect (maximum dose 300 mg).
Alternative: labetalol infusion.
Glyceryl trinitrate 10–200 μg/min infusion titrated to BP effect.
Nicardipine Avoid large BP falls in AIS.
5 mg/hour infusion titrated to BP effect.
Sodium nitroprusside Avoid in ICH due to antiplatelet effects.
0.5 μg/kg/min initial dose, infusion then titrated to BP effect.
Oral agents Swallowing assessment required, up to 50% of patients dysphagic.
Sublingual agents Rapidly absorbed, can cause steep falls in BP (limited data).
Transdermal agents Glyceryl trinitrate 5–10 mg/24-hour patch according to BP effect.
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of stroke to either stop or continue their pre-existing
antihypertensive medication for 2 weeks. Those who
continued their medication had a lower BP at 2 weeks
compared with those who stopped (mean difference
13 / 8 mm Hg). Death or dependency at 2 weeks (mRS
>3, primary outcome), death, major cardiovascular
events and serious adverse events at 6 months did not
differ between the two arms.110
The partial-factorial ENOS trial39 enrolled 2097
patients within 48 hours of stroke onset to continue or
stop their pre-stroke antihypertensive drugs for 7 days.
Although there was no effect on functional outcome
(mRS) at day 90, continuation of pre-stroke BP drugs
increased the risk of pneumonia (perhaps due to aspir-
ation), worsened BI and increased cognitive impairment
at 90 days.
When pooled data from COSSACS and ENOS were
reviewed, continuation of antihypertensives was asso-
ciated with worse disability (BI) and quality of life but
no change in functional outcome (mRS).23 This incon-
gruity is perplexing, but may represent chance, outcome
bias or indeed be real. If the latter is true and continu-
ing medication is detrimental, what is the mechanism?
First, giving medication to dysphagic patients without
appropriate enteral access could lead to aspiration and
resultant pneumonia.39 Second, as ACEi, ARA and
β-blocker drugs attenuate stress hormones, are common
preparations used prior to stroke, and are associated
with harm when given acutely after stroke (ARA and
β-blockers),29 31 it may be that continuing them in the
acute phase is potentially hazardous.23 It therefore
seems reasonable to pause existing antihypertensive
medication during the acute phase of stroke until
patients have suitable enteral access and are medically
and neurologically stable.23
CONCLUSION
Despite the recent publication of several large clinical
trials and systematic reviews, there are no deﬁnitive
recommendations that can be drawn regarding BP
modulation in AIS. BP should be lowered rapidly in
patients with ICH. Although stroke is more common in
the older population, trials to date have mostly involved
patients with a mean age of ≤75 years. Despite this,
there is no suggestion that older patients should not
have their BP lowered.89 In addition to age, further evi-
dence is needed on whether time of onset, stroke
subtype, severity, drug choice (dose, route and timing),
and BP variability inﬂuence response to changes in BP.
Individual patient data meta-analysis is warranted to aid
patient selection by identifying groups who are more or
less likely to beneﬁt and to establish whether a certain
drug class, dose, route or BP target is optimal.23
In summary, antihypertensives should be withheld
after stroke until they can be given safely in patients who
are neurologically stable. Both early intensive lowering
of BP in ICH and early nitrate use in all stroke subtypes
are safe and associated with improved functional
outcome. Whether these effects are mediated through
BP reduction or speciﬁc pharmacological effects incorp-
orating neuroprotection and/or reperfusion is unclear.
Time seems to be a key factor and so on-going and
future hyper-acute and ultra-acute trials are pivotal in
testing this hypothesis.
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